Milestone Pharmaceuticals Reports 2025 Financial Results and CARDAMYST Launch Update

MONTREAL and CHARLOTTE, N.C., March 20, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and full year ending December 31, 2025, and provided corporate and regulatory updates. The main drivers of the fourth quarter and full year 2025 activities include the U.S. Food and Drug Administration (FDA) approval of CARDAMYST™ (etripamil) nasal spray for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults and product launch during this transformational year.

Milestone Pharmaceuticals has recently released its financial results for the fourth quarter and the full year of 2025. The company is primarily focused on developing innovative treatments for cardiovascular diseases, and their flagship product, CARDAMYST (etripamil nasal spray), is designed to address acute paroxysmal atrial fibrillation (AFib).

For the fourth quarter of 2025, Milestone reported significant progress in their financial performance, reflecting a robust business strategy and successful operational execution. The company’s revenue growth can be attributed to the initial launch and early acceptance of CARDAMYST in the market. The management noted that the commercialization efforts have started to yield positive results, and they continue to ramp up marketing initiatives to maximize market penetration.

Throughout 2025, Milestone's expenses largely stemmed from research and development (R&D) activities, as well as costs associated with commercializing CARDAMYST. These investments are critical for ensuring a sustainable growth trajectory in the competitive pharmaceutical landscape. The company's R&D focus has been on not only improving the efficacy of their products but also enhancing patient experience through innovative delivery methods.

Milestone's update regarding the commercial launch of CARDAMYST highlights their strategy to engage healthcare providers and patients effectively. They have implemented various outreach programs to educate stakeholders about the benefits and usage of etripamil nasal spray. The management is optimistic about the continued trend of acceptance among cardiologists and healthcare institutions.

In addition to the launch of CARDAMYST, Milestone Pharmaceuticals is eyeing future advancements in their pipeline. The leadership team has emphasized the importance of expanding their portfolio to address unmet needs in cardiovascular treatment. This approach is expected to solidify the company’s position as a leader in the cardiovascular pharmaceuticals market.

Overall, Milestone's financial results and strategic updates provide a positive outlook on their business direction. With a commitment to innovation and patient care, the company aims to navigate challenges in the healthcare sector while delivering value to its stakeholders. The successful launch of CARDAMYST serves as a pivotal milestone for Milestone Pharmaceuticals, and they are poised for growth as they continue to address critical cardiovascular health issues.